Clinical Trial Update: PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC [Phase 2]

View source ↗

Summary

A phase 2 clinical trial at Johns Hopkins is evaluating PET-guided, response-adapted neoadjuvant therapy for triple-negative breast cancer and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING